Table 1.
Baseline characteristics of the study populationa
| Characteristic | % Complete | Calcitriol Users (n = 429) | Matched Controls (n = 989) |
|---|---|---|---|
| Demographics | |||
| Age | 100 | 69.0 ± 10.3 | 70.3 ± 10.3 |
| Male | 100 | 420 (97.9) | 974 (98.5) |
| Race | 71 | ||
| white | 263 (85.1) | 598 (86.4) | |
| black | 36 (11.7) | 70 (10.1) | |
| other | 10 (3.2) | 24 (3.5) | |
| Comorbidityb | |||
| diabetes | 100 | 276 (64.3) | 581 (58.7) |
| coronary heart disease | 100 | 90 (21.0) | 170 (17.2) |
| peripheral vascular disease | 100 | 112 (26.1) | 285 (28.8) |
| Charlson comorbidity indexc | 100 | 4.7 ± 2.0 | 4.5 ± 2.1 |
| eGFR | 100 | 31.1 ± 9.2 | 32.8 ± 10.4 |
| Baseline medication use | |||
| cholecalciferol or ergocalciferol | 100 | 35 (8.2) | 86 (8.7) |
| oral calcium | 100 | 118 (27.5) | 179 (18.1) |
| epoetin or darbepoetin | 100 | 65 (15.2) | 131 (13.2) |
| statin | 100 | 290 (67.6) | 579 (58.5) |
| ACEI or ARB | 100 | 267 (62.2) | 564 (57.0) |
| Body mass indexd | 98 | 31.0 ± 6.4 | 30.5 ± 6.6 |
| Systolic BP (mm/Hg)d | 98 | 142.1 ± 17.2 | 140.7 ± 17.9 |
| Laboratory valuesd | |||
| creatinine (mg/dL) | 100 | 2.6 ± 0.8 | 2.5 ± 0.8 |
| albumin (g/L) | 94 | 3.9 ± 0.4 | 3.9 ± 0.4 |
| hemoglobin (g/L) | 99 | 12.5 ± 1.7 | 12.6 ± 1.8 |
| calcium (mg/dL) | 100 | 8.9 ± 0.6 | 9.1 ± 0.5 |
| phosphate (mg/dL) | 99 | 3.8 ± 0.8 | 3.8 ± 0.8 |
| PTH (pg/dL) | 100 | 231.0 ± 127.2 | 145.1 ± 91.7 |
| Health care use | |||
| Nephrology visits during previous year | 100 | 2.8 ± 1.9 | 2.3 ± 1.8 |
| eGFR at nephrology referral | 97 | 36.4 ± 17.0 | 36.3 ± 14.7 |
| Prostate specific antigen screening (% of men) | 100 | 71 (17.4) | 190 (19.9) |
| Metropolitan VA Site | 100 | 346 (80.7) | 766 (77.5) |
a
Data are means ± SD or n (%). ACE, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker.
b
Comorbidity assessed using all previous medical information before the study start date.
c
Charlson comorbidity index calculated using hospitalization data from the previous year.
d
Outpatient measurements time averaged during the year before the study start date.